Key result
Higher BMI is linked to ~27% greater odds of moderate to severe hepatosteatosis in diabetes.
Why the study?
There is a close relationship between the development of diabetes and nonalcoholic fatty liver disease, but the frequency and associated factors of NAFLD in T2DM patients need further determination.
Observational (n=316)
No
Odds Ratio: 1.273 (95% CI 1.135–1.427)
p-value: p=<0.001
In patients with type 2 diabetes, NAFLD is highly prevalent (89.7%) and its severity is associated with BMI and hypertriglyceridemia.
High NAFLD rates in T2DM clinics may prompt metabolic risk review; leaves open prospective validation of noninvasive fibrosis indices.
Aim of the study:There is a close relationship between the development of diabetes and nonalcoholic fatty liver disease (NAFLD).The aim of the study was to determine the frequency and associated factors of NAFLD in type 2 diabetes mellitus (T2DM) patients according to the ultrasound examination and noninvasive hepatic fibrosis indices.Material and methods: 316 patients who were followed up in the Internal Medicine Diabetes clinic, over the age of 18, diagnosed with T2DM were included retrospectively.NAFLD was noted using ultrasound.NAFLD fibrosis score (NFS), fibrosis-4 index (FIB-4) and AST to platelet ratio index (APRI) were used as non-invasive hepatic fibrosis indices.Results: The prevalence of NAFLD with hepatic ultrasound was 89.7% in T2DM patients.Among non-invasive fibrosis indices, NFS and FIB-4 were similar, but APRI was significantly higher in moderate-severe hepatosteatosis group (p values = 0.355, 0.246 and 0.003 respectively).In logistic regression analysis, while mild hepatosteatosis was associated with BMI and NFS (p = 0.004, p = 0.008), moderate to severe hepatosteatosis as associated with BMI and serum triglycerides (p < 0.001, p = 0.019). Conclusions:The prevalence of NAFLD is high in patients with T2DM.The frequency and degree of NAFLD is associated with the NFS, BMI and hypertriglyceridemia.While NFS is associated with mild hepatosteatosis; moderate to severe hepatosteatosis is associated with BMI and serum triglycerides.
No takes yet. Share an insight, caveat, or question.
Akın et al. (2023) conducted an observational in Type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD) (n=316). Body mass index (BMI) vs. Cases without hepatosteatosis was evaluated on Presence of moderate to severe hepatosteatosis (OR 1.273, 95% CI 1.135-1.427, p=<0.001). In patients with type 2 diabetes, the prevalence of NAFLD was 89.7%, and moderate to severe hepatosteatosis was significantly associated with higher BMI (OR 1.273) and serum triglycerides.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: